Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

License and Option Agreements (Details) $ in Thousands	1 Months Ended		12 Months Ended
License and Option Agreements (Details) $ in Thousands	Nov. 30, 2020 USD ($) shares	Sep. 30, 2020 USD ($) item	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 shares	Apr. 30, 2023 USD ($)	Oct. 31, 2021 USD ($)	May 31, 2021 USD ($)	Oct. 31, 2020 USD ($)
Nature of Business
Accounts payable			$ 17,136	$ 5,396
Accrued expenses			39,371	17,306
2020 Xencor Agreement
Nature of Business
Number of antibody product candidates \| item		3
Agreement transaction price			0
2020 Xencor Agreement \| Series A preferred stock
Nature of Business
Fair value of initial consideration	$ 16,100
Number of preferred stock issued \| shares	5,041,542
2021 Xencor Agreement
Nature of Business
Development milestone expense payable			0				$ 10,000
Agreement transaction price					$ 20,700
Milestone payments									$ 10,000
Regulatory milestone payments									75,000
Sales milestone payments									$ 385,000
Dianthus Option Agreement
Nature of Business
Reimbursable costs			5,100	3,000
Number of antibody product candidates \| item		2
Threshold period to notify intention for exercising option		60 days
Accounts payable			500
Accrued expenses			300	400
Development milestone expense payable								$ 1,000
Milestone obligations		$ 11,000
Number of common stock issued \| shares						18,063
Viridian Agreement
Nature of Business
Reimbursable costs			$ 1,700	$ 0
Development milestone expense payable										$ 12,000
Number of common stock issued \| shares						38,707